Artiva Scraps Lead AlloNK Program After Grade 5 Safety Events, Cuts 94% of Staff
ARTV has more than doubled off its 52-week low of $2.96.
Summary
Artiva is discontinuing AlloNK, its lead NK-cell program, after updated data and recent Grade 5 safety events, and will not start the Phase 3 trial that the company had aligned with the FDA. The company is cutting roughly 94% of its workforce, a reduction it expects to complete in Q1 2027 with most wind-down costs incurred in Q4 2026, and is evaluating strategic alternatives including a sale, merger, asset deals, or liquidation, with Leerink Partners engaged as financial advisor for that review. Preliminary unaudited cash was about $319.1M at September 30, 2026, which now anchors the value case as a balance-sheet story rather than a clinical one. This reverses the narrative from the October 1 update, when updated Phase 2a Sjögren data was reported positively, and follows the August 6 8-K highlighting the RMAT designation for AlloNK. The equity is now a liquidation-value and asset-monetization trade; the key unknown is cash burn and liabilities through any wind-down.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Artiva engaged Leerink Partners as financial advisor for its strategic alternatives review and expects to complete the 94% workforce reduction in Q1 2027, incurring most wind-down costs in Q4 2026.
At the time of this announcement, ARTV was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.2M. The 52-week trading range was $2.96 to $14.53. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: Wiseek News.